Number of Patients in Phase I of the Study With a Confirmed HIV-1 RNA Viral Load ≤ 50 Copies/mL Between Week I-4 and Week I-12 of Phase I of the study [clinicaltrials_resource:4237983b07999dc6ac254e57ca6b0219]
Virologic responders were defined as patients who had an initial HIV-1 RNA assessment <= 50 copies/mL during Phase I at any visit between Week I-4 and Week I-12 and a confirmatory viral load assessment ≤ 50 copies/mL at the next visit (Week I-8 to Week II-16)
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
Number of Patients in Phase I of the Study With a Confirmed HIV-1 RNA Viral Load ≤ 50 Copies/mL Between Week I-4 and Week I-12 of Phase I of the study [clinicaltrials_resource:4237983b07999dc6ac254e57ca6b0219]
Virologic responders were defined as patients who had an initial HIV-1 RNA assessment <= 50 copies/mL during Phase I at any visit between Week I-4 and Week I-12 and a confirmatory viral load assessment ≤ 50 copies/mL at the next visit (Week I-8 to Week II-16)
Bio2RDF identifier
4237983b07999dc6ac254e57ca6b0219
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:4237983b07999dc6ac254e57ca6b0219
measure [clinicaltrials_vocabulary:measure]
Number of Patients in Phase I ...... RNA Viral Load ≤ 50 Copies/mL
time frame [clinicaltrials_vocabulary:time-frame]
Between Week I-4 and Week I-12 of Phase I of the study
description
Virologic responders were defi ...... visit (Week I-8 to Week II-16)
identifier
clinicaltrials_resource:4237983b07999dc6ac254e57ca6b0219
title
Number of Patients in Phase I ...... k I-12 of Phase I of the study
@en
type
label
Number of Patients in Phase I ...... 7983b07999dc6ac254e57ca6b0219]
@en